BIO Asia–Taiwan 2023 亞洲生技大會

BIO Asia–Taiwan 2023 亞洲生技大會

講師

Jeonghoon Ahn

Session 10 – Clinical Impacts of Precision Health

Date:27 July (Thursday)
Time15:40–17:10 (GMT+8)

Jeonghoon Ahn

Professor
Ewha Womans University

Dr. Jeonghoon Ahn is a full professor at the Ewha Womans University (Seoul, Korea) and an adjunct fellow at the National Evidence-based healthcare Collaborating Agency (NECA), Seoul, Korea. He is an expert on health technology assessment (HTA) and health economics. He worked 7 years in NECA (2009-2016) and served in various decision making and advisory committees of public agencies such as the Health Insurance Review and Assessment Services (HIRA), the National Health Insurance Services (NHIS), and the Korean Centers for Disease Control (KCDC). Professor Ahn has graduated the Seoul National University Department of International Economics for undergraduate and master program. He also received a PhD in Economics from the University of Southern California (USC) and was an assistant professor of pharmaceutical economics and Policy at the USC (2002-2009). Dr. Ahn has served on many international professional organizations such as ISPOR, HTAi, INAHTA, and HTAsiaLink. He is the Chair of the ISPOR Asia Consortium (2020-2022) and was a president of ISPOR Korea Chapter (2012-2014). Dr. Ahn was elected as a board director of the Health Technology Assessment International (HTAi) (2014-2016) and a board director for the International Network of Agencies for Health Technology Assessment (INAHTA) for three times (2012-2016). He also contributed to found a regional Health Technology Assessment agency network, the HTAsiaLink (www.htasialink.org), along with other experts in the region.

Speech title & Synopsis

HTA of Precision Medicine Diagnostics in Korea

A brief introduction of Korean healthcare system and Korean HTA system on three tacks (drugs, medical devices, and procedures/diagnostics) will be provided along with responsible institutions. Generally, it is a unique and complex system and some characteristics such as fee-for-service without any budget limitation but microscopic control on claim review process will be emphasized. For the precision medicine diagnostics in the Korean system, they are required to go through medical device track and also procedure/diagnostics tack if there is any associated fee schedule to perform the diagnostics. The procedures and details of HIRA expert committee on medical devices and NECA new health technology assessment committee (nHTA) along with NECA nHTA report will be explained. If time permits, some example of precision medicine nHTA reports will be presented.